文献速递头颈部肿瘤放疗

口咽癌加速轻度大分割放疗与传统分割放疗的长期吞咽结局相似:一项多中心研究

Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study.
PubMed 文献 · Radiother Oncol · 2022-05-17

这项多中心观察性研究纳入2015至2018年接受根治性放疗(未联合化疗)的口咽鳞状细胞癌患者,比较传统分割(70 Gy/35次/7周,n=97)与加速轻度大分割(65-66 Gy/30次/6周,n=136)的结局。两组局部区域控制与总生存相似,放疗期间肠内喂养率在7周组看似更高但未达统计学显著(59% vs 48%,p=0.08),放疗后1年喂养率相似(10% vs 6%,p=0.27);MDADI中位总体评分(60.0 vs 60.0,p=0.99)与复合评分(65.8 vs 64.2,p=0.44)无差异。作者认为加速轻度大分割可作为不适合同步化疗患者的标准治疗选择。

要点

  • 加速轻度大分割(65-66 Gy/30次/6周)与传统分割(70 Gy/35次/7周)的局部区域控制和总生存相似(p=0.78和0.95)。
  • 放疗期间肠内喂养率7周组59% vs 6周组48%(p=0.08),未达统计学显著;放疗后1年两组相似(10% vs 6%,p=0.27)。
  • MDADI中位总体评分6周组60.0 vs 7周组60.0(p=0.99),复合评分65.8 vs 64.2(p=0.44),无差异。

核心结论

  • 接受单纯放疗的口咽鳞状细胞癌患者,加速轻度大分割与传统分割方案的吞咽结局、局部区域控制和总生存相似,支持其作为不适合同步化疗患者的标准治疗选择。

研究设计与样本

  • 多中心观察性研究,连续纳入2015年至2018年接受根治性放疗(口咽及双侧颈部)的口咽鳞状细胞癌患者。
  • 传统分割组70 Gy/35次/7周,n=97;加速轻度大分割组65-66 Gy/30次/6周,n=136;均未联合化疗。
  • 放疗后至少2年无瘤存活的患者(n=151,65%)被发送MD Anderson吞咽困难量表(MDADI)问卷以评估吞咽功能。

主要发现

  • 局部区域控制和总生存在各方案间相似(p=0.78和0.95,log-rank检验)。
  • 放疗期间肠内喂养率7周组59% vs 6周组48%(p=0.08),未达统计学显著。
  • 放疗后1年喂养率两组相似(10% vs 6%,p=0.27)。
  • 107例患者返回MDADI问卷(71%);6周组与7周组中位总体评分60.0 vs 60.0(p=0.99),复合评分65.8 vs 64.2(p=0.44),无差异。

临床怎么用

  • 作者认为,加速轻度大分割可作为不适合同步化疗的口咽鳞状细胞癌患者的标准治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: There is renewed interest in hypofractionated radiotherapy, but limited data and a lack of consensus to support use for head and neck cancer. In this multicentre analysis we compared outcomes for patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with conventional and accelerated, mildly hypofractionated radiotherapy without chemotherapy. MATERIALS AND METHODS: A multi-centre, observational study of consecutive OPSCCs treated between 2015 and 2018. Patients underwent curative-intent radiotherapy (oropharyngeal and bilateral neck) using conventionally fractionated (70 Gy in 35 fractions over 7 weeks, n = 97) or accelerated, mildly hypofractionated (65-66 Gy in 30 fractions over 6 weeks, n = 136) radiotherapy without chemotherapy. Locoregional control (LRC) and overall survival (OS) were compared. Patients alive and cancer-free at a minimum of 2 years post-radiotherapy (n = 151, 65%) were sent an MD Anderson Dysphagia Inventory (MDADI) questionnaire to assess swallow function. RESULTS: LRC and OS were similar across schedules (p = 0.78 and 0.95 respectively, log-rank test). Enteral feeding rates during radiotherapy appeared higher in the 7-week group though this did not reach statistical significance (59% vs 48%, p = 0.08). Feeding rates were similar at 1 year post radiotherapy for both groups (10% vs 6%, p = 0.27). 107 patients returned MDADI questionnaires (71%); there were no differences between the 6- and 7-week groups for median global (60.0 vs 60.0, p = 0.99) and composite (65.8 vs 64.2, p = 0.44) MDADI scores. CONCLUSION: Patients with OPSCC treated with radiotherapy alone have similar swallowing outcomes, LRC and OS following accelerated, mild hypofractionation and standard fractionation schedules, supporting its use as a standard-of-care option for patients unsuitable for concurrent chemotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Price JM, West CM, Dixon LM, et al. Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study. Radiother Oncol. 2022. PMID: 35595173. doi:10.1016/j.radonc.2022.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。